<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nonrandomized and randomized trials of novel agents in advanced gastrointestinal neuroendocrine tumors (carcinoids)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nonrandomized and randomized trials of novel agents in advanced gastrointestinal neuroendocrine tumors (carcinoids)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Nonrandomized and randomized trials of novel agents in advanced gastrointestinal neuroendocrine tumors (carcinoids)</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16.6%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Molecular target(s)</td> <td class="subtitle1">Patients*</td> <td class="subtitle1">Objective tumor response rate (%)</td> <td class="subtitle1">Median TTP or PFS</td> <td class="subtitle1">Reference</td> </tr> <tr> <td class="subtitle2_left" colspan="6">VEGF pathway inhibitors</td> </tr> <tr> <td class="indent1" colspan="6"><strong>Phase II studies</strong></td> </tr> <tr> <td class="indent2">Bevacizumab</td> <td>VEGF</td> <td>22</td> <td>18<sup>¶</sup></td> <td>66 weeks</td> <td>Yao JC; 2008<sup>[1]</sup></td> </tr> <tr> <td class="indent2">Sunitinib</td> <td>VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT; RET; CSF-1R; FLT3</td> <td>41</td> <td>2</td> <td>10.2 months (TTP)</td> <td>Kulke MH; 2008<sup>[2]</sup></td> </tr> <tr> <td class="indent2">Sorafenib</td> <td>VEGFR-2, PDGFR, FGFR-1, BRAF</td> <td>50</td> <td>7<sup>Δ</sup></td> <td>7.8 months</td> <td>Hobday TJ; 2007<sup>[3]</sup></td> </tr> <tr> <td class="indent2" rowspan="3">Pazopanib</td> <td rowspan="3">VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT</td> <td>22</td> <td>0</td> <td>12.7 months</td> <td>Phan AT; 2015<sup>[4]</sup></td> </tr> <tr> <td>15 (GI tract)</td> <td rowspan="2">9</td> <td>10 months</td> <td rowspan="2">Grande E; 2015<sup>[5]</sup></td> </tr> <tr> <td>7 (lung, thymus)</td> <td>3.4 months</td> </tr> <tr> <td class="indent2">Cabozantinib</td> <td>VEGFR-2, MET, RET, AXL</td> <td>41</td> <td>15</td> <td>31.4 months</td> <td>Chan J; 2017<sup>[6]</sup></td> </tr> <tr> <td class="indent2">Lenvatinib</td> <td>VEGFR-1, -2, -3; FGFR-1, -2, -3, -4</td> <td>56 (GI tract)</td> <td>16</td> <td>15.7 months</td> <td>Capdevila J; 2021 (TALENT)<sup>[7]</sup></td> </tr> <tr> <td class="indent1" colspan="6"><strong>Randomized trials</strong></td> </tr> <tr> <td class="indent2">Octreotide + bevacizumab</td> <td rowspan="3">VEGF</td> <td>214</td> <td>12</td> <td>16.6 months (PFS)</td> <td rowspan="3">Yao JC; 2017 (SWOG S-0518)<sup>[8]</sup></td> </tr> <tr> <td class="indent3">versus</td> <td colspan="3"> </td> </tr> <tr> <td class="indent2">Octreotide + interferon</td> <td>213</td> <td>4</td> <td>15.4 months</td> </tr> <tr> <td class="indent2">Pazopanib</td> <td rowspan="3">VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT</td> <td>97</td> <td>2</td> <td>11.6 months</td> <td rowspan="3">Bergsland EK; 2019 (ALLIANCE A021202)<sup>[9]</sup></td> </tr> <tr> <td class="indent3">versus</td> <td colspan="3"> </td> </tr> <tr> <td class="indent2">Placebo</td> <td>74</td> <td>0</td> <td>8.5 months</td> </tr> <tr> <td class="indent2">Surufatinib</td> <td rowspan="3">VEGF-1,2,3; FGFR-1</td> <td>129</td> <td>10</td> <td>9.2 months</td> <td rowspan="3">Xu J; 2020 (SANET-ep)<sup>[10]</sup></td> </tr> <tr> <td class="indent3">versus</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent2">Placebo</td> <td>69</td> <td>0</td> <td>3.8 months</td> </tr> <tr> <td class="subtitle2_left" colspan="6">mTOR inhibitors</td> </tr> <tr> <td class="indent1" colspan="6"><strong>Phase II studies</strong></td> </tr> <tr> <td class="indent2">Everolimus</td> <td>mTOR</td> <td>30</td> <td>17</td> <td>63 weeks</td> <td>Yao JC; 2008<sup>[11]</sup></td> </tr> <tr> <td class="indent2">Temsirolimus</td> <td>mTOR</td> <td>21</td> <td>5</td> <td>6 months</td> <td>Duran I; 2006<sup>[12]</sup></td> </tr> <tr> <td class="indent1" colspan="6"><strong>Randomized trials</strong></td> </tr> <tr> <td class="indent2" colspan="2">Everolimus + octreotide LAR</td> <td>216</td> <td>2</td> <td>16.4 months</td> <td rowspan="3">Pavel ME; 2011 (RADIANT2)<sup>[13]</sup></td> </tr> <tr> <td class="indent3" colspan="5">versus</td> </tr> <tr> <td class="indent2" colspan="2">Placebo + octreotide LAR</td> <td>213</td> <td>2</td> <td>11.3 months</td> </tr> <tr> <td class="indent2" colspan="2">Everolimus + BSC</td> <td>205</td> <td>2</td> <td>11.0 months</td> <td rowspan="3">Yao JC; 2016 (RADIANT4)<sup>◊</sup><sup>[14]</sup></td> </tr> <tr> <td class="indent3" colspan="5">versus</td> </tr> <tr> <td class="indent2" colspan="2">Placebo + BSC</td> <td>97</td> <td>1</td> <td>3.9 months</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>TTP: time to tumor progression; PFS: progression-free survival; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; PDGFR: platelet-derived growth factor receptor; KIT: stem cell factor receptor; RET: rearranged during transfection or glial cell-line derived neurotrophic factor; CSF-1R: colony-stimulating factor 1 receptor; FLT3: fms-like tyrosine kinase 3; FGFR: fibroblast growth factor receptor; GI: gastrointestinal; SWOG: Southwest Oncology Group; mTOR: mammalian target of rapamycin; LAR: long-acting release; BSC: best supportive care.</p>
<p>* Number of patients evaluable for efficacy endpoints.</p>
<p>¶ Patients also received treatment with octreotide.</p>
<p>Δ Confirmed.</p>
◊ All patients had nonfunctioning neuroendocrine tumors of the lung or GI origin.</div><div class="graphic_reference">References:
<ol>
<li>Yao JC, Phan A, Hoff PM. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26:1316.</li>
<li>Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26:3403.</li>
<li>Hobday TJ, Rubin K, Holen J, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clinl Oncol 2007; 25:ASCO Annual Meeting Proceedings part I, abstract 4504.</li>
<li>Phan AT, Halperin DM, Chan JA, et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 2015; 16:695.</li>
<li>Grande E, Capdevila J, Castellano D, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol 2015; 26:1987.</li>
<li>Chan J, Faris JE, Murphy JE, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol 2017; suppl 4S:abstract 228.</li>
<li>Capdevila J, Fazio N, Lopez C, et al. Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: Results of the phase II TALENT trial (GETNE 1509). J Clin Oncol 2021; May 4;JCO2003368. doi: 10.1200/JCO.20.03368. (epub ahead of print).</li>
<li>Yao JC, Guthrie KA, Moran C, et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol 2017; 35:1695.</li>
<li>Bergsland EK, Mahoney MR, Asmis TR, et al. Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). J Clin Oncol 2019; 37:(suppl; abstr 4005).</li>
<li>Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21:1500.</li>
<li>Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311.</li>
<li>Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95:1148.</li>
<li>Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005.</li>
<li>Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387:968.</li>
</ol></div><div id="graphicVersion">Graphic 90847 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
